VANDA PHARMACEUTICALS INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
VANDA PHARMACEUTICALS INC. (VNDA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$48.20 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2019-08-01
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2019-06-30 was -$11.75M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2019-03-31 was -$36.45M, a 323.46% decline year-over-year.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-12-31 was -$15.80M, a 314.70% decline year-over-year.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-09-30 was -$8.90M, a 264.79% decline year-over-year.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2018 was -$109.66M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$10.23M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$10.03M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$26.60M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|
| 2019-06-30 | -$11.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$48.20M 10-Q · filed 2019-08-01 | -$64.01M derived: sum of 3 quarters · filed 2019-08-01 | -$72.91M derived: sum of 4 quarters · filed 2019-08-01 | |
| 2019-03-31 | -$36.45M 10-Q · filed 2019-05-03 | -$52.26M derived: sum of 2 quarters · filed 2019-05-03 | -$61.16M derived: sum of 3 quarters · filed 2019-05-03 | -$162.42M derived: sum of 4 quarters · filed 2019-08-01 | |
| 2018-12-31 | -$15.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | -$24.71M derived: sum of 2 quarters · filed 2019-02-19 | -$125.97M derived: sum of 3 quarters · filed 2019-08-01 | -$109.66M 10-K · filed 2019-02-19 | |
| 2018-09-30 | -$8.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$110.17M derived: sum of 2 quarters · filed 2019-08-01 | -$93.86M 10-Q · filed 2018-11-07 | -$86.50M derived: sum of 4 quarters · filed 2019-08-01 | |
| 2018-06-30 | -$101.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$84.95M 10-Q · filed 2019-08-01 | -$77.59M derived: sum of 3 quarters · filed 2019-08-01 | -$72.19M derived: sum of 4 quarters · filed 2019-08-01 | |
| 2018-03-31 | $16.31M 10-Q · filed 2019-05-03 | $23.67M derived: sum of 2 quarters · filed 2019-05-03 | $29.08M derived: sum of 3 quarters · filed 2019-05-03 | $23.25M derived: sum of 4 quarters · filed 2019-05-03 | |
| 2017-12-31 | $7.36M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $12.77M derived: sum of 2 quarters · filed 2019-02-19 | $6.94M derived: sum of 3 quarters · filed 2019-02-19 | -$10.23M 10-K · filed 2019-02-19 | -$10.11M 10-K · filed 2018-02-15 |
| 2017-09-30 | $5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$424.00K derived: sum of 2 quarters · filed 2018-11-07 | -$17.59M 10-Q · filed 2018-11-07 | -$9.46M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2017-06-30 | -$5.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$23.00M 10-Q · filed 2018-08-02 | -$14.86M derived: sum of 3 quarters · filed 2019-02-19 | -$12.49M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2017-03-31 | -$17.17M 10-Q · filed 2018-05-02 | -$9.03M derived: sum of 2 quarters · filed 2019-02-19 | -$6.67M derived: sum of 3 quarters · filed 2019-02-19 | -$19.96M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2016-12-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $10.50M derived: sum of 2 quarters · filed 2019-02-19 | -$2.80M derived: sum of 3 quarters · filed 2019-02-19 | -$10.03M 10-K · filed 2019-02-19 | -$10.07M 10-K · filed 2017-02-17 |
| 2016-09-30 | $2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$10.93M derived: sum of 2 quarters · filed 2017-11-08 | -$18.16M 10-Q · filed 2017-11-08 | -$13.74M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-06-30 | -$13.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$20.53M 10-Q · filed 2017-08-03 | -$16.11M derived: sum of 3 quarters · filed 2018-02-15 | -$16.39M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-03-31 | -$7.23M 10-Q · filed 2017-05-03 | -$2.81M derived: sum of 2 quarters · filed 2018-02-15 | -$3.09M derived: sum of 3 quarters · filed 2018-02-15 | -$258.00K derived: sum of 4 quarters · filed 2018-02-15 | |
| 2015-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $4.13M derived: sum of 2 quarters · filed 2018-02-15 | $6.97M derived: sum of 3 quarters · filed 2018-02-15 | -$26.60M 10-K · filed 2018-02-15 | |
| 2015-09-30 | -$279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $2.56M derived: sum of 2 quarters · filed 2016-11-03 | -$31.01M 10-Q · filed 2016-11-03 | -$59.52M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | $2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | -$30.73M 10-Q · filed 2016-07-28 | -$59.24M derived: sum of 3 quarters · filed 2017-02-17 | -$53.53M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | -$33.57M 10-Q · filed 2016-05-05 | -$62.08M derived: sum of 2 quarters · filed 2017-02-17 | -$56.36M derived: sum of 3 quarters · filed 2017-02-17 | -$45.99M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | -$28.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$22.79M derived: sum of 2 quarters · filed 2017-02-17 | -$12.43M derived: sum of 3 quarters · filed 2017-02-17 | -$12.04M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $5.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $16.08M derived: sum of 2 quarters · filed 2015-11-04 | $16.47M 10-Q · filed 2015-11-04 | -$49.23M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-06-30 | $10.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $10.76M 10-Q · filed 2015-07-31 | -$54.94M derived: sum of 3 quarters · filed 2016-02-12 | -$54.95M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-03-31 | $389.00K 10-Q · filed 2015-05-07 | -$65.31M derived: sum of 2 quarters · filed 2016-02-12 | -$65.31M derived: sum of 3 quarters · filed 2016-02-12 | ||
| 2013-12-31 | -$65.70M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | -$65.70M derived: sum of 2 quarters · filed 2016-02-12 | -$34.27M 10-K · filed 2016-02-12 | ||
| 2013-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | $31.42M 10-Q · filed 2014-10-27 | |||
| 2013-06-30 | $31.43M 10-Q · filed 2014-08-08 | ||||
| 2012-12-31 | $45.75M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |